Moderated By: Jim Langdon -- (Not Moderated) -- Started: 8/5/1996 8:27:00 PM Revision History
Anyone follow this small biotech company. Its lead drug is Norcalcin for the treatment of HPT. Norcalcin is starting the second phase trials and mimicks the action of calcium by activating the calcium receptor. Recently Amgen has signed a 43.5 million dollar deal to develop and market the drug. Recently touted by George Southerland in his newsletter. Any comments apprriciated! |
Copyright © 1995-2013 Knight Sac Media. All rights reserved.